The Cancer Biomarkers Research Group promotes research to identify, develop, and validate biological markers for early cancer detection and cancer risk assessment. Activities include development and validation of promising cancer biomarkers, collaborative databases and informatics systems, and new technologies or the refinement of existing technologies.
Read more About the Cancer Biomarkers Research Group.
Alliance of Glycobiologists for Cancer Research
Tumor Glycomics Laboratories work to reveal cancer-related dynamics of complex carbohydrates.
Consortium for Imaging and Biomarkers (CIB)
Research Units integrate imaging strategies with biomarkers to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and diagnosis of early stage cancer.
Consortium for Molecular Characterization of Screen-Detected Lesions
Seven laboratories and a coordinating center focus on identifying screening-detected pre-cancers and early cancers, including within the tumor microenvironment.
Early Detection Research Network (EDRN)
Labs and centers bring together comprehensive infrastructure and resources critical to discovery, development and validation of biomarkers for cancer risk and early detection.
Liquid Biopsy Consortium
A partnership with academic and industrial laboratory teams developing noninvasive liquid biopsy techniques to detect early stage cancer from biomarkers in blood, urine and sputum.
Pancreatic Cancer Detection Consortium (PCDC)
Research teams develop and test new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma and its precursor lesions.
Translational Liver Cancer (TLC) Consortium
Five Translational Research Centers conduct studies to improve surveillance of liver cancer in high-risk populations, increase detectability at early stages, and stratify at-risk patients.
The Search for Early Detection of Pancreatic Cancer Accelerates with Biomarkers
Scientists have identified more than 1,000 potential new biomarkers for cancer that they hope will aid in the early detection of many of these complex diseases, including one of the most challenging, pancreatic cancer.
New Technology Gives Patients Access to a 5-Minute, Office-Based Test to Identify Risk for Esophageal Cancer
A new technology coupled with a new biomarker test now in clinical trials are giving patients timely access to a quick, accurate and less invasive way to identify risk for one type of esophageal cancer. EsoCheck™ and EsoGuard™ are the device and test created for the detection of Barrett's esophagus, the benign and treatable precursor condition to esophageal adenocarcinomas (EAC).
Taking Advantage of the Transportation Processes from Inside to Outside the Cell to Detect Cancer
As cancer researchers delve into the many molecular processes that guide cell life within the body, NCI is looking for ways to characterize and measure different substances in this process, with an eye to identifying who has cancer or who is at risk for the disease.
New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development
The National Cancer Institute is leading a project to create a cohort of people who are newly diagnosed with diabetes in the hopes that this group, who are at increased risk of developing pancreatic cancer, provide the clues in their blood and tissues to unravel some of the unknowns about this highly fatal cancer. The New Onset Diabetes Study (NOD) will include 10,000 people ages 50 to 85...